Page 367 - Cote clinical veterinary advisor dogs and cats 4th

Chemotherapy: Adverse Events 154.e1

ADDITIONAL SUGGESTED RELATED CLIENT EDUCATION
READINGS SHEETS
VetBooks.ir London C: Tyrosine kinase inhibition in veterinary Consent to Administer Chemotherapy Diseases and Disorders
medicine. Top Companion Anim Med 24:106-112,
How to Syringe-Feed, Tube-Feed, or Bottle-Feed
2009.
a Pet
MacDonald V: Chemotherapy: managing side effects
and safe handling. Can Vet J 50:665-668, 2009. Leukemia
Mealey KL, et al: Breed distribution of the ABCB1- Lymphoma, Gastrointestinal
1Delta (multidrug sensitivity) polymorphism among Lymphoma, Peripheral or Multicentric
dogs undergoing ABCB1 genotyping. J Am Vet Mammary Gland Neoplasia
Med Assoc 233:921-924, 2008. Mast Cell Tumors
Thamm DH, et al: Aftershocks of cancer chemo-
therapy: managing adverse effects. J Am Anim Mesothelioma
Hosp Assoc 43:1-7, 2007. Squamous Cell Carcinoma
Vail DM: Supporting veterinary cancer patient on
chemotherapy: neutropenia and gastrointestinal
toxicity. Top Companion Anim Med 24:122-129,
2009.
Vail DM, et al: Assessment of GS-9219 in a pet dog
model of non-Hodgkin’s lymphoma. Clin Cancer
Res 15:3503-3510, 2009.
Venable RO, et al: Dexrazoxane for treatment of
doxorubicin extravasation injury in four dogs. J
Am Vet Med Assoc 240:304-307, 2012.
Veterinary cooperative oncology group—common
terminology criteria for adverse events (VCOG-
CTCAE) following chemotherapy or biological
antineoplastic therapy in dogs and cats v1.1. Vet
Comp Oncol 14:417-446, 2016.

www.ExpertConsult.com